Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down15.660 -0.220 (-1.385%)

12/10/2021 15:47

Hansoh Pharma (03692) units sign licensing agreement

[ET Net News Agency, 12 October 2021] Hansoh Pharmaceutical Group Company Limited
(03692) said Hansoh (Shanghai) Health Technology Co., Ltd. and Jiangsu Hansoh
Pharmaceutical Group Company Ltd. (collectively, the licensees), each a wholly-owned
subsidiary of the company, have entered into an exclusive licence and collaboration
agreement with OliX Pharmaceuticals, Inc. (KOSDAQ: 226950) (OliX Pharmaceuticals).
OliX Pharmaceuticals will use its GalNAc-asiRNA platform technology to discover lead
compounds and secure development candidates for targets in cardiovascular, metabolic, and
other diseases associated with the liver. Hansoh will have the exclusive commercial rights
to these therapeutics in China (including Hong Kong, Macau and Taiwan) and OliX
Pharmaceuticals will have the rights in the rest of the world. OliX Pharmaceuticals will
receive initial upfront payment of US$6.5 million with up to US$450 million plus royalties
based on key milestones. (RC)

Remark: Real time quote last updated: 28/01/2022 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2022 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.